Market closedNon-fractional
Arrowhead Pharmaceuticals/ARWR
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Ticker
ARWR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Pasadena, United States
Employees
525
Website
arrowheadpharma.com
ARWR Metrics
BasicAdvanced
$3.1B
Market cap
-
P/E ratio
-$4.23
EPS
0.78
Beta
-
Dividend rate
Price and volume
Market cap
$3.1B
Beta
0.78
Financial strength
Current ratio
8.311
Quick ratio
7.993
Long term debt to equity
79.646
Total debt to equity
80.713
Interest coverage (TTM)
-20.57%
Management effectiveness
Return on assets (TTM)
-32.07%
Return on equity (TTM)
-99.43%
Valuation
Price to revenue (TTM)
79.06
Price to book
6.48
Price to tangible book (TTM)
6.48
Price to free cash flow (TTM)
-5.97
Growth
Revenue change (TTM)
-87.00%
Earnings per share change (TTM)
199.06%
3-year revenue growth
-26.44%
3-year earnings per share growth
58.30%
What the Analysts think about ARWR
Analyst Ratings
Majority rating from 14 analysts.
ARWR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$125M
-5.65%
Profit margin
0.00%
-100.00%
ARWR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.96
-$1.02
-$1.24
-$1.02
-
Expected
-$0.65
-$0.60
-$0.82
-$0.16
-$0.54
Surprise
47.01%
69.09%
51.22%
528.01%
-
ARWR News
AllArticlesVideos
Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course
Business Wire·1 week ago
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Business Wire·1 week ago
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $3.1B as of July 04, 2024.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of July 04, 2024.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Arrowhead Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.